



Complete Summary

GUIDELINE TITLE

Benign prostatic hyperplasia.

BIBLIOGRAPHIC SOURCE(S)

Finnish Medical Society Duodecim. Benign prostatic hyperplasia. In: EBM Guidelines. Evidence-Based Medicine [Internet]. Helsinki, Finland: Wiley Interscience. John Wiley & Sons; 2008 Sep 27 [Various].

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: Finnish Medical Society Duodecim. Benign prostatic hyperplasia. In: EBM Guidelines. Evidence-Based Medicine [Internet]. Helsinki, Finland: Wiley Interscience. John Wiley & Sons; 2007 Apr 16 [Various].

COMPLETE SUMMARY CONTENT

SCOPE
METHODOLOGY - including Rating Scheme and Cost Analysis
RECOMMENDATIONS
EVIDENCE SUPPORTING THE RECOMMENDATIONS
BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS
IMPLEMENTATION OF THE GUIDELINE
INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT
CATEGORIES
IDENTIFYING INFORMATION AND AVAILABILITY
DISCLAIMER

SCOPE

DISEASE/CONDITION(S)

Benign prostatic hyperplasia

GUIDELINE CATEGORY

Diagnosis
Evaluation
Treatment

CLINICAL SPECIALTY

Family Practice
Internal Medicine
Urology

INTENDED USERS

Health Care Providers
Physicians

GUIDELINE OBJECTIVE(S)

Evidence-Based Medicine Guidelines collect, summarize, and update the core clinical knowledge essential in general practice. The guidelines also describe the scientific evidence underlying the given recommendations.

TARGET POPULATION

Men with suspected or confirmed benign prostatic hyperplasia

INTERVENTIONS AND PRACTICES CONSIDERED

Diagnosis/Evaluation

Primary Investigations

1. Assessment of signs and symptoms
 - Storage symptoms
 - Voiding symptoms
2. Symptom questionnaire (e.g., International Prostatic Symptom Score [IPSS])
3. Writing down details associated with voiding
4. Digital rectal examination (DRE)
5. Urinalysis
6. Serum/plasma creatinine
7. Serum prostate-specific antigen (PSA)
8. Residual urine volume as determined by ultrasonography or catheterization
9. Differential diagnosis
10. Specialist consultation when indicated

Investigations Performed by Urologist

1. Urine flow measurement
2. Transrectal ultrasonography
3. Cystometry and pressure-flow examination
4. Urethrocystography
5. Urography
6. Prostatic biopsies
7. Cystoscopy

Treatment

1. Conservative treatment
 - Follow-up
2. Drug treatment
 - Alpha₁-blockers
 - 5-alpha-reductase inhibitors
 - Combination of 5-alpha-reductase inhibitor and alpha₁-blocker
3. Surgical and other invasive treatments
 - Transurethral resection of the prostate (TURP)
 - Transurethral incision of the prostate (TUIP)
 - Open prostatectomy
 - Green laser treatment
 - Thermotherapy (microwave treatment)
 - Stent or spiral
4. Catheter
 - Percutaneous cystostomy or catheterization
 - Repeated catheterization
 - A silicon catheter with the balloon filled with hypertonic (5%) saline or glyserol

Follow-up Treatment after TURP

1. Urine bacterial culture
2. Antibiotics (if bacterial infection is detected)
3. Pelvic floor muscle exercises for stress incontinence
4. Antimuscarinic drugs for urge incontinence and nocturia

MAJOR OUTCOMES CONSIDERED

- Effect of treatment on factors such as symptoms, prostate volume, peak urinary flow, residual urine volume, urinary flow rate, risk of overall clinical progression
- Adverse effects of treatment

METHODOLOGY

METHODS USED TO COLLECT/SELECT EVIDENCE

Hand-searches of Published Literature (Primary Sources)
 Hand-searches of Published Literature (Secondary Sources)
 Searches of Electronic Databases

DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE

The evidence reviewed was collected from the Cochrane database of systematic reviews and the database of abstracts of reviews of effectiveness (DARE). In addition, the Cochrane Library and medical journals were searched specifically for original publications.

NUMBER OF SOURCE DOCUMENTS

Not stated

METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE

Weighting According to a Rating Scheme (Scheme Given)

RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE

Classification of the Quality of Evidence

Code	Quality of Evidence	Definition
A	High	Further research is very unlikely to change our confidence in the estimate of effect. <ul style="list-style-type: none">• Several high-quality studies with consistent results• In special cases: one large, high-quality multi-centre trial
B	Moderate	Further research is likely to have an important impact on confidence in the estimate of effect and may change the estimate. <ul style="list-style-type: none">• One high-quality study• Several studies with some limitations
C	Low	Further research is very likely to have an important impact on confidence in the estimate of effect and is likely to change the estimate. <ul style="list-style-type: none">• One or more studies with severe limitations
D	Very Low	Any estimate of effect is very uncertain. <ul style="list-style-type: none">• Expert opinion• No direct research evidence• One or more studies with very severe limitations

GRADE (Grading of Recommendations Assessment, Development and Evaluation) Working Group 2007 (modified by the EBM Guidelines Editorial Team).

METHODS USED TO ANALYZE THE EVIDENCE

Systematic Review

DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE

Not stated

METHODS USED TO FORMULATE THE RECOMMENDATIONS

Not stated

RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS

Not applicable

COST ANALYSIS

A formal cost analysis was not performed and published cost analyses were not reviewed.

METHOD OF GUIDELINE VALIDATION

Peer Review

DESCRIPTION OF METHOD OF GUIDELINE VALIDATION

Not stated

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

The levels of evidence [A-D] supporting the recommendations are defined at the end of the "Major Recommendations" field.

Aims

- The diagnosis of benign prostatic hyperplasia is based on symptoms and basic investigations. Other causes of voiding disturbances (prostate cancer in particular) are excluded.
- Conditions requiring surgical management are recognized.
- Follow-up alone or drug therapy are good options in patients with relatively mild symptoms and no complications of urinary tract stricture.

Symptoms

- Storage symptoms
 - Extraordinary voiding frequency
 - Nocturia
 - Urinary urgency
 - Urge incontinence
- Voiding symptoms
 - Difficulty in the initiation of voiding

- Poor urine flow
- Need to strain while voiding
- Discontinued voiding
- Feeling of inadequate bladder emptying
- Urinary retention

Primary Investigations

- Symptom questionnaire
 - A commonly used questionnaire is International Prostatic Symptom Score (IPSS) (See Questionnaire List in the original guideline document).
 - The questionnaire is useful in the assessment of severity of symptoms when decisions are made between follow-up, drug treatment, and surgery.
- Writing down details associated with voiding
- DRE (digital rectum examination)
- Urinalysis
- Serum/plasma creatinine
- Serum prostate-specific antigen (PSA)
- Residual urine volume is determined by ultrasonography (see the Finnish Medical Society Duodecim guideline "Determining the Volume of Residual Urine by Ultrasonography") (See Video 1 in the original guideline document) (or, if ultrasonography is not available, by catheterization). Ultrasonography is useful in the determination of prostatic size (calculated with the same equation as residual urine volume [see the Finnish Medical Society Duodecim guideline "Determining the Volume of Residual Urine by Ultrasonography"]), shape, and eventual hydronephrosis.
- Differential diagnosis, see table below.

Table: Differential Diagnosis on Benign Prostatic Hyperplasia

Condition or Disease	History or Finding
Prostate cancer	Finding in digital rectal exam (DRE), elevated serum PSA concentration
Urinary bladder cancer	Haematuria, abnormal cytological finding
Bladder calculi	Haematuria, ultrasonography finding
Urethral stricture	Box-shaped flow curve
Stricture of the bladder neck	Earlier invasive treatment
Bladder neck dyssynergia	Small prostate gland, disturbing symptoms associated with voiding

Condition or Disease**History or Finding**

Prostatitis

Tender prostate gland

Overactive bladder

Urgency with possible urge incontinence

Indications for Specialist Consultation**Indications for Diagnostic Investigations by the Urologist**

- The patient is below 50 years of age.
- DRE is suspicious (nodules or induration).
- Serum PSA is above 10 micrograms/L (above 3 micrograms/L in patients below 65 years of age).
 - If the serum total PSA concentration is in the range of 3 to 10 micrograms/L, measuring free/total PSA ratio is recommended. If this value is under 0.15, the probability of prostatic cancer is increased (Walsh, 1996) and a urologist should be consulted.
 - DRE before determination of serum PSA level does not influence the result.
- Rapidly developing symptoms
- Haematuria (cystoscopy)
- Diabetics who may have neuropathy
- History of pelvic surgery or irradiation
- Neurological disease or injury affecting the function of the urinary bladder
- Necessary medication affecting the function of the urinary bladder
- Lower abdominal pain as the main symptom
- Discrepancy between symptoms and findings
- The investigations performed by the urologist usually include:
 - Urine flow measurement
 - Transrectal ultrasonography
- And if necessary also
 - Cystometry and pressure-flow examination (recommended before deciding on surgery if the peak flow is >10 mL/s and also when there is a discrepancy between symptoms and findings or the patient has undergone surgery of the lower urinary tract)
 - Urethrocystography
 - Urography
 - Prostatic biopsies
 - Cystoscopy

Surgical Treatment Is Indicated in the Following Cases

- Urinary retention, overflow incontinence, or repeatedly more than 300 mL of residual urine
- Severe symptoms not relieved by drug therapy
- Severe narrowing based on measurement of flow rate
- Dilatation of the upper urinary tract
- Impairment of renal function

- Recurrent macroscopic haematuria
- Urinary tract infections
- Bladder calculi
- Severe or moderate symptoms in a patient who wants rapid relief or if satisfactory results have not been obtained with other treatments

Conservative Treatment

Follow-up

- As the symptoms of benign prostatic hyperplasia (BPH) vary greatly and the course of the disease in an individual cannot be fully predicted, follow-up is a suitable approach in patients with mild symptoms. Also in moderate symptoms, follow-up can be the initial approach if the symptoms do not essentially affect the quality of life and complications have not developed.
- Follow-up includes explaining to the patient the nature of the disease and carrying out basic investigations annually or when symptoms have changed. Opportunistic follow-up during other encounters in primary care is one method of screening.

Drug Treatment

- Although the effectiveness of drug treatment is not as good as that of surgery it is often sufficient for reducing or alleviating the symptoms.
- When deciding on the treatment, cost-effectiveness should also be evaluated (i.e., when would invasive therapy, which usually gives complete cure, cost less and be more convenient for the patient than drug therapy continuing for years). Transurethral resection is more cost-effective than drug treatment.
- Patients on drug treatment should be followed up regularly at 6- to 12-month intervals to detect complications resulting from urethral obstruction.
- The size of the prostate and total serum PSA determine the selection of the therapy (Boyle, Gould, & Roehrborn, 1996; Boyle et al., 2003) **[A]**. If the prostate is not markedly enlarged on palpation or in ultrasonography (<30 mL) and PSA is <1.5 micrograms/L, the first choice is an α_1 -blocker (e.g., tamsulosin or alfuzosin) (Lepor et al., 1996; Boyle, Gould, & Roehrborn, 1996). If the prostate is markedly enlarged or PSA is >1.5 micrograms/L, either 5- α -reductase inhibitor (finasteride, dutasteride) (Wilde & Goa, 1999; Roehrborn et al., 2002; Debruyne et al., 2004) **[A]** or an α_1 -blocker can be used.
- A combination of 5- α -reductase inhibitor and α_1 -blocker alleviates symptoms more effectively than either drug alone (McConnell et al., 2003) **[A]**.

Alpha-blockers

- Tamsulosin (Wilt, MacDonald, & Rutks, 2002) **[A]**, alfuzosin, doxazosin, terazosin, and prazosin.
- α_1 -blockers (Webber, 2005) **[A]** decrease symptoms, increase peak urinary flow, and reduce the volume of residual urine significantly more than placebo.
- The effect of α_1 -blockers is seen rapidly, and it has been shown to continue for several years.

- The patients should be followed up initially at 1- to 3-month intervals.
- The side effects include dizziness, postural hypotension, and missing of ejaculation, which is more rare with alfuzosin than with tamsulosin. With selective tamsulosin and alfuzosin the risk of hypotension is lower.

5-Alpha-Reductase Inhibitors (5ARI)

- The dose of finasteride is 5 mg x 1 and that of dutasteride is 0.5 mg x 1.
- The symptoms are alleviated, the urine flow is increased, and the obstruction is decreased (Wilde & Goa, 1999; Roehrborn et al., 2002; Debruyne et al., 2004) **[A]**.
- The effect is at its best in patients with large prostates (Boyle, Gould, & Roehrborn, 1996; Boyle, Roehrborn, & Marks, 2003) **[A]** (Walsh, 1996).
- The effect starts slowly, sometimes as late as 6 months after the onset of treatment. If no effect is observed in 6 months the indications for surgery should be reconsidered.
- The drug decreases prostatic size but the prostate returns to its original size a few months after discontinuation of treatment.
- Impotence may occur as an adverse effect.
- Although treatment with 5-alpha-reductase inhibitors decreases serum PSA level by about 50% this makes follow-up no more difficult than with alpha-blockers: an increasing PSA concentration is an indication for investigation by a urologist.

Surgical and Other Invasive Treatments

- Transurethral resection of the prostate (TURP) (Webber, 2005) **[A]**
 - The only treatment for complicated prostatic hyperplasia and the best documented treatment for uncomplicated disease
 - Results very seldom in erectile dysfunction (though in most cases already before operation), almost always retrograde ejaculation
- Transurethral incision of the prostate (TUIP)
 - Suitable for patients with prostates <30 mL in volume and with no prominent median lobe protruding towards the bladder
- Open prostatectomy
 - Rarely used nowadays (prostate >100 mL)
- Green laser treatment
 - An alternative to transurethral resection
 - Data on the outcomes in long-term follow-up are lacking.
- Thermotherapy (microwave treatment) (Hoffman et al., 2007) **[A]**
 - Alleviates irritative symptoms
 - Long-term results are not available
- Stent or spiral
 - Can be used in selected cases in patients with a poor general condition

Catheter

- Percutaneous cystostomy is indicated in patients with urinary retention waiting for surgery (good skills in the insertion technique required). In selected cases repeated catheterization can be used (preferably by the patient himself).

- A silicon catheter with the balloon filled with hypertonic (5%) saline or glyserol can be used, but percutaneous cystostomy is preferred.

Treatment after TURP

- Urine bacterial culture should be taken routinely 4 to 6 weeks after the operation to detect bacteriuria, and always if a urinary tract infection is suspected (pyuria and haematuria may occur as long as 3 months after the operation).
- If bacterial growth is detected, antibiotics are indicated.
- Stress incontinence may be alleviated within 1 year: exercises of pelvic floor muscles may help (Hunter, Glazener, & Moore, 2007) **[D]**.
- Antimuscarinic drugs (oxybutynin, tolterodine, trospium chloride, solifenacin, or darifenacin) can be used for the treatment of urge incontinence and nocturia.

Related Resources

Refer to the original guideline document for related evidence, including Cochrane reviews and other evidence summaries.

Definitions:

Classification of the Quality of Evidence

Code	Quality of Evidence	Definition
A	High	Further research is very unlikely to change our confidence in the estimate of effect. <ul style="list-style-type: none"> • Several high-quality studies with consistent results • In special cases: one large, high-quality multi-centre trial
B	Moderate	Further research is likely to have an important impact on confidence in the estimate of effect and may change the estimate. <ul style="list-style-type: none"> • One high-quality study • Several studies with some limitations
C	Low	Further research is very likely to have an important impact on confidence in the estimate of effect and is likely to change the estimate. <ul style="list-style-type: none"> • One or more studies with severe limitations
D	Very Low	Any estimate of effect is very uncertain.

Code	Quality of Evidence	Definition
		<ul style="list-style-type: none"> • Expert opinion • No direct research evidence • One or more studies with very severe limitations

GRADE (Grading of Recommendations Assessment, Development and Evaluation) Working Group 2007 (modified by the EBM Guidelines Editorial Team).

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

REFERENCES SUPPORTING THE RECOMMENDATIONS

[References open in a new window](#)

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

Concise summaries of scientific evidence attached to the individual guidelines are the unique feature of the Evidence-Based Medicine Guidelines. The evidence summaries allow the clinician to judge how well-founded the treatment recommendations are. The type of supporting evidence is identified and graded for select recommendations (see the "Major Recommendations" field).

BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

POTENTIAL BENEFITS

Appropriate diagnostic evaluation and treatment of benign prostatic hyperplasia

Subgroups of Patients within Target Population Most Likely to Benefit

Finasteride is most effective in men with large prostates.

POTENTIAL HARMS

- Side effects of α_1 -blockers include dizziness, postural hypotension, and retrograde ejaculation.
- Finasteride may cause impotence.
- Transurethral resection of the prostate may cause urinary tract infection, stress incontinence, urge incontinence, nocturia, retrograde ejaculation, and very seldom, erectile dysfunction.

IMPLEMENTATION OF THE GUIDELINE

DESCRIPTION OF IMPLEMENTATION STRATEGY

An implementation strategy was not provided.

IMPLEMENTATION TOOLS

Quick Reference Guides/Physician Guides
Resources

For information about [availability](#), see the "Availability of Companion Documents" and "Patient Resources" fields below.

INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

IOM CARE NEED

Getting Better
Living with Illness

IOM DOMAIN

Effectiveness

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

Finnish Medical Society Duodecim. Benign prostatic hyperplasia. In: EBM Guidelines. Evidence-Based Medicine [Internet]. Helsinki, Finland: Wiley Interscience. John Wiley & Sons; 2008 Sep 27 [Various].

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

2001 Apr 30 (revised 2008 Sep 27)

GUIDELINE DEVELOPER(S)

Finnish Medical Society Duodecim - Professional Association

SOURCE(S) OF FUNDING

Finnish Medical Society Duodecim

GUIDELINE COMMITTEE

Editorial Team of EBM Guidelines

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Primary Author: Teuvo Tammela

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: Finnish Medical Society Duodecim. Benign prostatic hyperplasia. In: EBM Guidelines. Evidence-Based Medicine [Internet]. Helsinki, Finland: Wiley Interscience. John Wiley & Sons; 2007 Apr 16 [Various].

GUIDELINE AVAILABILITY

This guideline is included in "EBM Guidelines. Evidence-Based Medicine" available from Duodecim Medical Publications, Ltd, PO Box 713, 00101 Helsinki, Finland; e-mail: info@ebm-guidelines.com; Web site: www.ebm-guidelines.com.

AVAILABILITY OF COMPANION DOCUMENTS

The following are available:

- Benign prostatic hyperplasia. Quick Guide.
- Residual urine volume (ultrasonography). Video 1.

Electronic copies available to subscribers from [Finnish Medical Society Duodecim Web site](http://www.duodecim.fi).

PATIENT RESOURCES

None available

NGC STATUS

This summary was completed by ECRI on August 28, 2001. The information was verified by the guideline developer as of October 26, 2001. This summary was updated by ECRI on December 9, 2002, December 29, 2003, July 15, 2004, February 18, 2005, and November 2, 2005. This summary was updated by ECRI on November 30, 2005 following the U.S. Food and Drug Administration (FDA) advisory on Flomax. This summary was updated by ECRI on December 26, 2006,

and again on November 12, 2007. This summary was updated by ECRI Institute on January 6, 2009.

COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <http://www.guideline.gov/about/inclusion.aspx>.

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

© 1998-2009 National Guideline Clearinghouse

Date Modified: 3/9/2009

